PURPOSE: To investigate the expression of SUMO-1 in human hepatocellular carcinoma (HCC) cell lines and clinical HCC samples. METHODS: RT-PCR and Western blot were used to detect the expressions of SUMO-1 in HCC cell lines, clinical HCC samples,and the non-neoplastic liver tissues adjacent to HCC. After transfection of SUMO-1 siRNA into HCC cell line SMMC-7721, the expression levels of Bcl-2, c-Myc and α-tubulin were examined, and MTT assay and cell cycle analysis were carried out as well. RESULTS: Overexpressions of SUMO-1 were detected in HCC cell lines and clinical HCC samples, while the expression level of SUMO-1 in the non-neoplastic liver tissues was significantly lower (P < 0.001). Transfection of SUMO-1 siRNA resulted in 73.43% of maximal silencing efficiency of SUMO-1 in 48 h. The expressions of Bcl-2 and c-Myc were down-regulated coincidentally. SUMO-1 siRNA notably inhibited SMMC-7721 cells proliferation in vitro and increased the ratios of G2 phase and S phase in the cells. CONCLUSIONS: Owing to overexpression of SUMO-1 in HCC and its important role in the development of HCC, SUMO-1 could be a latent target in diagnosis and therapy of HCC.
PURPOSE: To investigate the expression of SUMO-1 in humanhepatocellular carcinoma (HCC) cell lines and clinical HCC samples. METHODS: RT-PCR and Western blot were used to detect the expressions of SUMO-1 in HCC cell lines, clinical HCC samples,and the non-neoplastic liver tissues adjacent to HCC. After transfection of SUMO-1 siRNA into HCC cell line SMMC-7721, the expression levels of Bcl-2, c-Myc and α-tubulin were examined, and MTT assay and cell cycle analysis were carried out as well. RESULTS: Overexpressions of SUMO-1 were detected in HCC cell lines and clinical HCC samples, while the expression level of SUMO-1 in the non-neoplastic liver tissues was significantly lower (P < 0.001). Transfection of SUMO-1 siRNA resulted in 73.43% of maximal silencing efficiency of SUMO-1 in 48 h. The expressions of Bcl-2 and c-Myc were down-regulated coincidentally. SUMO-1 siRNA notably inhibited SMMC-7721 cells proliferation in vitro and increased the ratios of G2 phase and S phase in the cells. CONCLUSIONS: Owing to overexpression of SUMO-1 in HCC and its important role in the development of HCC, SUMO-1 could be a latent target in diagnosis and therapy of HCC.
Authors: K I Kim; S H Baek; Y J Jeon; S Nishimori; T Suzuki; S Uchida; N Shimbara; H Saitoh; K Tanaka; C H Chung Journal: J Biol Chem Date: 2000-05-12 Impact factor: 5.157
Authors: Stefanie Weidtkamp-Peters; Thorsten Lenser; Dmitri Negorev; Norman Gerstner; Thomas G Hofmann; Georg Schwanitz; Christian Hoischen; Gerd Maul; Peter Dittrich; Peter Hemmerich Journal: J Cell Sci Date: 2008-07-29 Impact factor: 5.285
Authors: N Gopalakrishna Iyer; Suet-Feung Chin; Hilal Ozdag; Yataro Daigo; De-En Hu; Massimiliano Cariati; Kevin Brindle; Samuel Aparicio; Carlos Caldas Journal: Proc Natl Acad Sci U S A Date: 2004-04-27 Impact factor: 11.205
Authors: Anita C Bellail; Hong Ri Jin; Ho-Yin Lo; Sung Han Jung; Chafiq Hamdouchi; Daeho Kim; Ryan K Higgins; Maximilian Blanck; Carlos le Sage; Benedict C S Cross; Jing Li; Amber L Mosley; Aruna B Wijeratne; Wen Jiang; Manali Ghosh; Yin Quan Zhao; Paula M Hauck; Anantha Shekhar; Chunhai Hao Journal: Sci Transl Med Date: 2021-10-13 Impact factor: 19.319
Authors: Dingyin Tao; Jonas G King; Rebecca E Tweedell; Philipp J Jost; Justin A Boddey; Rhoel R Dinglasan Journal: Mol Cell Proteomics Date: 2014-02-16 Impact factor: 5.911
Authors: Ronald Koschny; Sylvia Brost; Ulf Hinz; Jaromir Sykora; Emanuela M Batke; Stephan Singer; Kai Breuhahn; Wolfgang Stremmel; Henning Walczak; Peter Schemmer; Peter Schirmacher; Tom M Ganten Journal: BMC Cancer Date: 2013-11-09 Impact factor: 4.430